Viral Venereal Diseases of the Skin.
Alphapapillomavirus
/ isolation & purification
Combined Modality Therapy
/ methods
Counseling
/ standards
Dermatology
/ methods
Herpesviridae
/ isolation & purification
Herpesviridae Infections
/ diagnosis
Humans
Mass Screening
/ standards
Papillomavirus Infections
/ diagnosis
Practice Guidelines as Topic
Prevalence
Risk Factors
Sexually Transmitted Diseases, Viral
/ diagnosis
Skin
/ pathology
Skin Diseases, Viral
/ diagnosis
Journal
American journal of clinical dermatology
ISSN: 1179-1888
Titre abrégé: Am J Clin Dermatol
Pays: New Zealand
ID NLM: 100895290
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
accepted:
28
04
2021
pubmed:
20
5
2021
medline:
14
9
2021
entrez:
19
5
2021
Statut:
ppublish
Résumé
Viral venereal diseases remain difficult to treat. Human papilloma virus (HPV) and herpes simplex virus (HSV) are two common viral venereal diseases. HPV infections are characterized by anogenital warts and less commonly by premalignant or malignant lesions. HSV infections classically present as grouped vesicles on an erythematous base with associated burning or pain; however, immunosuppressed patients may have atypical presentations with nodular or ulcerative lesions. This review discusses the epidemiology, diagnosis, and management of anogenital HPV and HSV infections with an emphasis on treatment modalities for the practicing dermatologist. Diagnosis of these diseases typically relies on clinical assessment, although multiple diagnostic techniques can be utilized and are recommended when diagnosis is uncertain or evaluating an individual with increased risk of malignancy. Management of HPV and HSV infections involves appropriate counseling, screening, and multiple treatment techniques. Particularly for HPV infections, a practitioner may need to use a combination of techniques to achieve the desired outcome.
Identifiants
pubmed: 34008162
doi: 10.1007/s40257-021-00606-7
pii: 10.1007/s40257-021-00606-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
523-540Références
Chen Z, DeSalle R, Schiffman M, Herrero R, Wood CE, Ruiz JC, et al. Niche adaptation and viral transmission of human papillomaviruses from archaic hominins to modern humans. PLoS Pathog. 2018;14:e1007352.
pubmed: 30383862
pmcid: 6211759
Wertheim JO, Smith MD, Smith DM, Scheffler K, Kosakovsky Pond SL. Evolutionary origins of human herpes simplex viruses 1 and 2. Mol Biol Evol. 2014;31:2356–64.
pubmed: 24916030
pmcid: 4137711
Bowden R, Sakaoka H, Ward R, Donnelly P. Patterns of Eurasian HSV-1 molecular diversity and inferences of human migrations. Infect Genet Evol. 2006;6:63–74.
pubmed: 16376841
CDC HPV Case Definition. https://www.cdc.gov/std/stats18/appendix-c.htm . Accessed 1 Feb 2021.
Bornstein J, Bogliatto F, Haefner HK, Stockdale CK, Preti M, Bohl TG, et al. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) Terminology of vulvar squamous intraepithelial lesions. Obstet Gynecol. 2016;127:264–8.
pubmed: 26942352
Darragh TM, Colgan TJ, Thomas Cox J, Heller DS, Henry MR, Luff RD, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: Background and consensus recommendations from the college of American pathologists and the American society for colposcopy and cervical pathology. Int J Gynecol Pathol. 2013;32:76–115.
pubmed: 23202792
Gross G. Bowenoid Papulosis. Arch Dermatol. 1985;121:858.
pubmed: 2990353
Wilkinson EJ, Cox JT, Selim MA, O’Connor DM. Evolution of terminology for human-papillomavirus-infection-related vulvar squamous intraepithelial lesions. J Low Genit Tract Dis. 2015;19:81–7.
pubmed: 24832173
Wieland U, Jurk S, Weissenborn S, Pfister H, Krieg T, Ritzkowsky A. Erythroplasia of Queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. J Invest Dermatol. 2000;115:396–401.
pubmed: 10951274
Grassegger A, Höpfl R, Hussl H, Wicke K, Fritsch P. Buschke—Loewenstein tumour infiltrating pelvic organs. Br J Dermatol. 1994;130:221–5.
pubmed: 8123576
Vidal CI, Armbrect EA, Andea AA, Bohlke AK, Comfere NI, Hughes SR, et al. Appropriate use criteria in dermatopathology: initial recommendations from the American Society of Dermatopathology. J Am Acad Dermatol. 2019;80:189-207.e11.
pubmed: 29689323
Szentirmay Z, Pólus K, Tamás L, Szentkuti G, Kurcsics J, Csernák E, et al. Human papillomavirus in head and neck cancer: Molecular biology and clinicopathological correlations. Cancer Metast Rev. 2005;24:19–34.
Mui U, Haley C, Tyring S. Viral oncology: molecular biology and pathogenesis. J Clin Med. 2017;6:111.
pmcid: 5742800
Stubenrauch F, Laimins LA. Human papillomavirus life cycle: Active and latent phases. Semin Cancer Biol. 1999;9:379–86.
pubmed: 10712884
Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.
pubmed: 15830458
Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, Hgødall E, Geertsen PF, Havsteen H. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. J Clin Oncol. 2014;32:1812–7.
pubmed: 24821878
Halec G, Alemany L, Quiros B, Clavero O, Höfler D, Alejo M, et al. Biological relevance of human papillomaviruses in vulvar cancer. Mod Pathol. 2017;30:549–62.
pubmed: 28059099
Aynaud O, Ionesco M, Barrasso R. Penile intraepithelial neoplasia. Specific clinical features correlate with histologic and virologic findings. Cancer. 1994;74:1762–7.
pubmed: 8082079
Chan KW, Lam KY, Chan ACL, Lau P, Srivastava G. Prevalence of human papillomavirus types 16 and 18 in penile carcinoma: A study of 41 cases using PCR. J Clin Pathol. 1994;47:823–6.
pubmed: 7962651
pmcid: 494939
Micali G, Nasca MR, Innocenzi D, Schwartz RA. Penile cancer. J Am Acad Dermatol. 2006;54:369–91.
pubmed: 16488287
Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol. 2001;8:209–20.
pubmed: 11238198
pmcid: 96039
Kim SC, Glynn RJ, Giovannucci E, Hernández-Díaz S, Liu J, Feldman S, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015;74:1360–7.
pubmed: 24618265
Wadström H, Frisell T, Sparén P, Askling J. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. Ann Rheum Dis. 2016;75:1272–8.
pubmed: 26755797
Matorras R, Ariceta JM, Rementeria A, Corral J, de Terán GG, Diez J, et al. Human immunodeficiency virus-induced immunosuppression: a risk factor for human papillomavirus infection. Am J Obstet Gynecol. 1991;164:42–4.
pubmed: 1846062
Halpert RG, Fruchter RG, Sedlis A, Butt K, Boyce JC, Sillman FH. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol. 1986;68:251–8.
pubmed: 3016625
Wadström H, Arkema EV, Sjöwall C, Askling J, Simard JF. Cervical neoplasia in systemic lupus erythematosus: a nationwide study. Rheumatol (United Kingdom). 2017;56:613–9.
Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500–10.
pubmed: 10995805
Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005;32:7.
Oriel JD. Natural history of genital warts. Sex Transm Infect. 1971;47:1–13.
Arima Y, Winer RL, Feng Q, Hughes JP, Lee SK, Stern ME, et al. Development of genital warts after incident detection of human papillomavirus infection in young men. J Infect Dis. 2010;202:1181–4.
pubmed: 20812849
Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191:731–8.
pubmed: 15688287
Burchell AN, Winer RL, de Sanjosé S, Franco EL. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24:52–61.
Winer RL, Hughes JP, Feng Q, O’Reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354:2645–54.
pubmed: 16790697
Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC, Giuliano AR. Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis. 2004;31:601–7.
pubmed: 15388997
Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41:660–4.
pubmed: 25299412
pmcid: 6745688
Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195:1582–9.
pubmed: 17471427
Flagg EW, Torrone EA. Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006–2014. Am J Public Health. 2018;108:112–9.
pubmed: 29161070
pmcid: 5719685
Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003;36:1397–403.
pubmed: 12766834
Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005;23:1107–22.
pubmed: 16277547
Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004;191:105–13.
pubmed: 15295350
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Heal. 2020;8:e191-203.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
pubmed: 26742998
De Vuyst H, Lillo F, Broutet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev. 2008;17:545–54.
pubmed: 18941376
Gormley RH, Kovarik CL. Human papillomavirus-related genital disease in the immunocompromised host: Part I. J Am Acad Dermatol Elsevier. 2012;66:883.e1-883.e17.
Dong H, Shu D, Campbell TM, Frühauf J, Soyer P, Hofmann-Wellenhof R. Dermatoscopy of genital warts. J Am Acad Dermatol. 2011;64:859–64.
pubmed: 21429619
Leonardi CL, Zhu WY, Kinsey WH, Penneys NS. Seborrheic keratoses from the genital region may contain human papillomavirus DNA. Arch Dermatol. 1991;127:1203–6.
pubmed: 1650542
Li J, Ackerman AB. “Seborrheic keratoses” that contain human papillomavirus are condylomata acuminata. Am J Dermatopathol. 1994;16:398–408.
pubmed: 7978069
Reutter JC, Geisinger KR, Laudadio J. Vulvar seborrheic keratosis: Is there a relationship to human papillomavirus? J Low Genit Tract Dis. 2014;18:190–4.
pubmed: 24556611
Cho CY, Lo YC, Hung MC, Lai CC, Chen CJ, Wu KG. Risk of cancer in patients with genital warts: a nationwide, population-based cohort study in Taiwan. PLoS ONE. 2017;12:1–15.
Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for cervical cancer us preventive services task force recommendation statement. JAMA J Am Med Assoc. 2018;320:674–86.
Nguyen ML, Flowers L. Cervical cancer screening in immunocompromised women. Obstet Gynecol Clin N Am. 2013;40:339–57.
Moscicki AB, Flowers L, Huchko MJ, Long ME, MacLaughlin KL, Murphy J, et al. Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis. 2019;23:87–101.
pubmed: 30907775
ACOG. Management of vulvar intraepithelial neoplasia. Gynaecol. Perinatol. 2016;128:1–5.
Sinclair KA, Woods CR, Kirse DJ, Sinal SH. Anogenital and respiratory tract human papillomavirus infections among children: Age, gender, and potential transmission through sexual abuse. Pediatrics. 2005;116:815–25.
pubmed: 16199688
Dominiak-Felden G, Cohet C, Atrux-Tallau S, Gilet H, Tristram A, Fiander A. Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK. BMC Public Health. 2013;13:1–11.
Bertolotti A, Milpied B, Fouéré S, Cabié A, Dupin N, Derancourt C. Methodologic gaps and risk of bias in randomized controlled trials of local anogenital wart treatments. J Am Acad Dermatol. 2019;81:1197–8.
pubmed: 30953705
Barton S, Wakefield V, O’mahony C, Edwards S. Effectiveness of topical and ablative therapies in treatment of anogenital warts: a systematic review and network meta-analysis. BMJ Open. 2019;9:1–10.
Jung JM, Jung CJ, Lee WJ, Won CH, Lee MW, Choi JH, et al. Topically applied treatments for external genital warts in nonimmunocompromised patients: a systematic review and network meta-analysis. Br J Dermatol. 2020;183:24–36.
pubmed: 31675442
Eron LJ, Judson F, Tucker S, Prawer S, Mills J, Murphy K, et al. Interferon therapy for condylomata acuminata. N Engl J Med. 1986;315:1059–64.
pubmed: 3531860
Trial AMDPC, Edin F. Recurrent condylomata acuminata treated with recombinant interferon alfa-2a. JAMA. 1991;265:2684.
Stanley MA. Imiquimod and the imidazoquinolones: Mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002;27:571–7.
pubmed: 12464152
Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small-antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196–200.
pubmed: 11812998
Grillo-Ardila CF, Gaitán HG, Angel-Müller E, Ruiz-Parra AI, Lethaby A. Imiquimod for anogenital warts in non-immunocompromised adults. Cochrane Database Syst Rev. 2013:CD010389.
Beutner KR, Tyring SK, Trofatter KF, Douglas JM, Spruance S, Owens ML, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother. 1998;42:789–94.
pubmed: 9559784
pmcid: 105543
Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol. 1998;134:25–30.
pubmed: 9449906
Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas J. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol. 1998;38:230–9.
pubmed: 9486679
Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, Van De Kerkhof PCM, et al. Topical immunomodulation under systemic immunosuppression: Results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. 2007;157:25–31.
pubmed: 18067628
pmcid: 2493058
Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol. 2005;141:985–93.
pubmed: 16103328
Herrera S, Correa LA, Wolff JC, Gaviria A, Tyring SK, Sanclemente G. Effect of imiquimod in anogenital warts from HIV-positive men. J Clin Virol. 2007;39:210–4.
pubmed: 17513167
Sanclemente G, Herrera S, Tyring SK, Rady PL, Zuleta JJ, Correa LA, et al. Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. J Eur Acad Dermatology Venereol. 2007;21:1054–60.
Wilson L. Properties of colchicine binding protein from chick embryo brain. Interactions with vinca alkaloids and podophyllotoxin. Biochemistry. 1970;9:4999–5007.
pubmed: 5480163
Lacey CJN, Woodhall SC, Wikstrom A, Ross J. 2012 European guideline for the management of anogenital warts. J Eur Acad Dermatology Venereol. 2013;27:263–70.
Culp OS, Magid MA, Kaplan IW. Podophyllin treatment of condylomata Acuminata. J Urol. 1944;51:655–60.
Kaplan IW. Condylomata acuminata. New Orleans Med Surg. 1942;94:388–90.
Lacey CJN, Goodall RL, Ragnarson Tennvall G, Maw R, Kinghorn GR, Fisk PG, et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect. 2003;79:270–5.
pubmed: 12902571
pmcid: 1744726
Edwards A, Atma-Ram A, Thin RN. Podophyllintoxin 0.5% v podophyllin 20% to treat penile warts. Genitourin Med. 1988;64:263–5.
pubmed: 3169757
pmcid: 1194230
Kinghorn GR, McMillan A, Mulcahy F, Drake S, Lacey C, Bingham JS. An open, comparative, study of the efficacy of 0.5% podophyllotoxin lotion and 25% podophyllotoxin Solution in the treatment of condylomata acuminata in males and females. Int J STD AIDS. 1993;4:194–9.
pubmed: 8399497
Mohanty KC. The cost effectiveness of treatment of genital warts with podophyllotoxin. Int J STD AIDS. 1994;5:253–6.
pubmed: 7948154
Slater GE, Rumack BH, Peterson RG. Podophyllin poisoning. Systemic toxicity following cutaneous application. Obstet Gynecol. 1978;52:94–6.
pubmed: 683634
Moher LM, Maurer SA. Podophyllum toxicity: case report and literature review. J Fam Pract. 1979;9:237–40.
pubmed: 458391
Fisher AA. Severe systemic and local reactions to topical podophyllum resin. Cutis. 1981;28:233 (236, 242 passim).
pubmed: 6457731
Rosen T. Green tea catechins: biologic properties, proposed mechanisms of action, and clinical implications. J Drugs Dermatol. 2012;11:e55-60.
pubmed: 23135094
Nguyen HP, Doan HQ, Brunell DJ, Rady P, Tyring SK. Apoptotic gene expression in sinecatechins-treated external genital and perianal warts. Viral Immunol. 2014;27:556–8.
pubmed: 25275942
Rösl F, Das BC, Lengert M, Geletneky K, zur Hausen H. Antioxidant-induced changes of the AP-1 transcription complex are paralleled by a selective suppression of human papillomavirus transcription. J Virol. 1997;71:362–70.
pubmed: 8985358
pmcid: 191059
Tatti S, Stockfleth E, Beutner KR, Tawfik H, Elsasser U, Weyrauch P, et al. Polyphenon E®: A new treatment for external anogenital warts. Br J Dermatol. 2010;162:176–84.
pubmed: 19709100
Tatti S, Swinehart JM, Thielert C, Tawfik H, Mescheder A, Beutner KR. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol. 2008;111:1371–9.
pubmed: 18515521
Gross G, Meyer KG, Pres H, Thielert C, Tawfik H, Mescheder A. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon® E in the treatment of external genital warts. J Eur Acad Dermatol Venereol. 2007;21:1404–12.
pubmed: 17958849
Stockfleth E, Beti H, Orasan R, Grigorian F, Mescheder A, Tawfik H, et al. Topical Polyphenon® E in the treatment of external genital and perianal warts: A randomized controlled trial. Br J Dermatol. 2008;158:1329–38.
pubmed: 18363746
Handley JM, Horner T, Maw RD, Lawther H, Dinsmore WW. Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: A randomised observer blind placebo controlled study. Genitourin Med. 1991;67:297–302.
pubmed: 1916791
pmcid: 1194704
Damstra R, van Vloten W. Cryotherapy in the treatment of condylomata acuminata: a controlled study of 64 patients. J Dermatol Surg Oncol. 1991;17:273–6.
pubmed: 2005249
Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex Transm Dis. 1993;20:344–5.
pubmed: 8108758
Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, et al. External genital warts: Diagnosis, treatment, and prevention. Clin Infect Dis. 2002;35:S210–24.
pubmed: 12353208
Duus BR, Philipsen T, Christensen JD, Lundvall F, Søndergaard J. Refractory condylomata acuminata: a controlled clinical trial of carbon dioxide laser versus conventional surgical treatment. Genitourin Med. 1985;61:59–61.
pubmed: 3936774
pmcid: 1011758
Lindkaer JS. Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata. Lancet. 1985;326:1146–8.
Orlando G, Fasolo MM, Beretta R, Merli S, Cargnel A. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS. 2002;16:447–50.
pubmed: 11834957
Khawaja HT. Podophyllin versus scissor excision in the treatment of perianal condylomata acuminata: a prospective study. Br J Surg. 1989;76:1067–8.
pubmed: 2597953
Kofoed K, Norrbom C, Forslund O, Møller C, Frøding LP, Pedersen AE, et al. Low prevalence of oral and nasal human papillomavirus in employees performing CO2-laser evaporation of genital warts or loop electrode excision procedure of cervical dysplasia. Acta Derm Venereol. 2015;95:173–6.
pubmed: 24941064
Sawchuk WS, Weber PJ, Lowy DR, Dzubow LM. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: Detection and protection. J Am Acad Dermatol. 1989;21:41–9.
pubmed: 2545749
Hallmo P, Naess O. Laryngeal papillomatosis with human papillomavirus DNA contracted by a laser surgeon. Eur Arch Oto-rhino-laryngology. 1991;248:425–7.
Sherrard J, Riddell L. Comparison of the effectiveness of commonly used clinic-based treatments for external genital warts. Int J STD AIDS. 2007;18:365–8.
pubmed: 17609022
Godley MJ, Bradbeer CS, Gellan M, Thin RNT. Cryotherapy compared with trichloroacetic acid in treating genital warts. Sex Transm Infect. 1987;63:390–2.
Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1–137.
pubmed: 26042815
pmcid: 5885289
Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol Res. 1998;10:523–31.
pubmed: 10338155
Snoeck R, Bossens M, Parent D, Delaere B, Degreef H, Van Ranst M, et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis. 2001;33:597–602.
pubmed: 11477525
Anshelevich EE, Barbieri JS, Kovarik CL. Intralesional cidofovir for treatment of recalcitrant warts in both immunocompetent and immunocompromised patients: a retrospective analysis of 58 patients. J Am Acad Dermatol. 2020;84:206–7.
pubmed: 32348821
Bienvenu B, Martinez F, Devergie A, Rybojad M, Rivet J, Bellenger P, et al. Topical use of cidofovir induced acute renal failure. Transplantation. 2002;73:661–2.
pubmed: 11889450
Batista CS, Atallah ÁN, Saconato H, da Silva EMK. 5-FU for genital warts in non-immunocompromised individuals. Cochrane Database Syst Rev. 2020;2010:CD006562.
Recanati MA, Kramer KJ, Maggio JJ, Chao CR. Cadtharadin is superior to trichloroacetic acid for treatment of non-mucosal genital warts: a pilot randomized controlled trial. Clin Exp Obs Gynecol. 2018;45:383–6.
Yang J, Guo PY, Ming ZZ, Jian YZ, Huang N, Wen DQ. Interferon for the treatment of genital warts: a systematic review. BMC Infect Dis. 2009;9:156.
pubmed: 19772554
pmcid: 2754484
Hasumi K. A trial of topical idoxuridine for vulvar condyloma acuminatum. BJOG An Int J Obstet Gynaecol. 1987;94:366–8.
Happonen HP, Lassus A, Santalahti J, Forsstrom S, Lassus J. Topical idoxuridine for treatment of genital warts in males. A double-blind comparative study of 0.25% and 0.5% cream. Genitourin Med. 1990;66:254–6.
pubmed: 2202655
pmcid: 1194524
Kreuter A, Wieland U. Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients. J Am Acad Dermatol. 2013;68:179–80.
pubmed: 23244376
Lee HJ, Kim JK, Kim DH, Yoon MS. Condyloma accuminatum treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18). J Am Acad Dermatol. 2011;64:130–2.
Creasman C, Haas PA, Fox TA, Balazs M. Malignant transformation of anorectal giant condyloma acuminatum (Buschke-Loewenstein tumor). Dis Colon Rectum. 1989;32:481–7.
pubmed: 2791784
Chu QD, Vezeridis MP, Libbey NP, Wanebo HJ. Giant condyloma acuminatum (Buschke-Lowenstein tumor) of the anorectal and perianal regions—analysis of 42 cases. Dis Colon Rectum. 1994;37:950–7.
pubmed: 8076499
De Toma G, Cavallaro G, Bitonti A, Polistena A, Onesti MG, Scuderi N. Surgical management of perianal giant condyloma acuminatum (Buschke-Löwenstein tumor). Eur Surg Res. 2006;38:418–22.
pubmed: 16902304
Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML. High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum. 2008;51:829–37.
pubmed: 18363070
Schneider A, Hotz M, Gissmann L. Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women. Int J Cancer. 1987;40:198–201.
pubmed: 3038757
Kemp EA, Hakenewerth AM, Laurent SL, Gravitt PE, Stoerker J. Human papillomavirus prevalence in pregnancy. Obstet Gynecol. 1992;79:649–56.
pubmed: 1314358
Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in pregnancy and lactation. 11th ed. Philadelphia, PA: Wolters Kluwer; 2017.
Andersson NW, Andersen JT. Association between fetal safety outcomes and exposure to local podophyllotoxin during pregnancy. JAMA Dermatol. 2020;156:303–11.
pubmed: 31913405
pmcid: 6990942
Ciavattini A, Tsiroglou D, Vichi M, Di Giuseppe J, Cecchi S, Tranquilli AL. Topical Imiquimod 5% cream therapy for external anogenital warts in pregnant women: report of four cases and review of the literature. J Matern Neonatal Med. 2012;25:873–6.
Schwartz DB, Greenberg MD, Daoud Y, Reid R. Genital condylomas in pregnancy: Use of trichloroacetic acid and laser therapy. Am J Obstet Gynecol. 1988;158:1407–16.
pubmed: 3381865
Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol. 2003;101:645–52.
pubmed: 12681865
Patsner B, Baker DA, Orr JW. Human papillomavirus genital tract infections during pregnancy. Clin Obstet Gynecol. 1990;33:258–67.
pubmed: 2161719
CDC Child and Adolescent Vaccination Schedule. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html# . Accessed 1 Feb 2021.
CDC Adult Vaccination Schedule. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html#note-hpv . Accessed 1 Feb 2021.
Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis. 1998;26:541–53.
pubmed: 9524821
Sucato G, Wald A, Wakabayashi E, Vieira J, Corey L. Evidence of latency and reactivation of both herpes simplex virus (HSV)- 1 and HSV-2 in the genital region. J Infect Dis. 1998;177:1069–72.
pubmed: 9534984
Frampton AR, Goins WF, Nakano K, Burton EA, Glorioso JC. HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther. 2005;12:891–901.
pubmed: 15908995
Roizman B, Whitley RJ. An inquiry into the molecular basis of HSV latency and reactivation. Annu Rev Microbiol. 2013;67:355–74.
pubmed: 24024635
Doll JR, Hoebe K, Thompson RL, Sawtell NM. Resolution of herpes simplex virus reactivation in vivo results in neuronal destruction. PLoS Pathog. 2020;16:1–28.
Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000;342:844–50.
pubmed: 10727588
Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA J Am Med Assoc. 2011;305:1441–9.
Wald A, Ericsson M, Krantz E, Selke S, Corey L. Oral shedding of herpes simplex virus type 2. Sex Transm Infect. 2004;80:272–6.
pubmed: 15295123
pmcid: 1744863
Docherty JJ, Trimble JJ, Roman SR, Faulkner SC, Naugle FP, Mundon FK, et al. Lack of oral HSV-2 in a college student population. J Med Virol. 1985;16:283–7.
pubmed: 2993498
Wald A. Genital HSV-1 infections. Sex Transm Infect. 2006;82:189–90.
pubmed: 16731663
pmcid: 2564733
Mertz GJ, Coombs RW, Ashley R, Jourden J, Remington M, Winter C, et al. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis. 1988;157:1169–77.
pubmed: 2836518
Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995;333:770–5.
pubmed: 7643884
Mertz GJ, Beneditti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116:197–202.
pubmed: 1309413
Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med. 1992;116:433.
pubmed: 1310837
pmcid: 4084907
Wald A, Zeh J, Selke S, Warren T, Ashley R, Corey L. Genital shedding of herpes simplex virus among men. J Infect Dis. 2002;186:S34–9.
pubmed: 12353185
Krone MR, Wald A, Tabet SR, Paradise M, Corey L, Celum CL. Herpes simplex virus type 2 shedding in human immunodeficiency virus—negative men who have sex with men: frequency, patterns, and risk factors. Clin Infect Dis. 2000;30:261–7.
pubmed: 10671325
Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350:11–20.
pubmed: 14702423
Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini IM, Self SG, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One. 2008;3:e2230.
pubmed: 18493617
pmcid: 2377333
Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20:73–83.
pubmed: 16327322
Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: A meta-analysis. J Infect Dis. 2002;185:45–52.
pubmed: 11756980
Koelle DM, Abbo H, Peck A, Ziegweid K, Corey L. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J Infect Dis. 1994;169:956–61.
pubmed: 8169426
Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, et al. Negative mucosal synergy between herpes simplex type 2 and HIV in the female genital tract. AIDS. 2007;21:589–98.
pubmed: 17314521
Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. J Am Med Assoc. 1998;280:61–6.
Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Bañez Ocfemia CM, et al. Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40:187–93.
pubmed: 23403598
McQuillan G, Kruszon-Moran D, Flagg EW, Paulose-Ram R. Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14-49: United States, 2015-2016. NCHS Data Brief. 2018:1–8.
Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. J Am Med Assoc. 2006;296:964–73.
Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2-United States, 1999–2010. J Infect Dis. 2014;209:325–33.
pubmed: 24136792
Corey L, Adams H, Brown Z, Holmes K. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983;98:958.
pubmed: 6344712
Johnston C, Magaret A, Selke S, Remington M, Corey L, Wald A. Herpes simplex virus viremia during primary genital infection. J Infect Dis. 2008;198:31–4.
pubmed: 18471083
Lautenschlager S, Eichmann A. The heterogeneous clinical spectrum of genital herpes. Dermatology. 2001;202:211–9.
pubmed: 11385226
Sasso BM, Florence MEB, Magalhaes RF, Velho PENF, de Souza EM, Cintra ML. Herpes simplex virus mucocutaneous tumoural lesions—systematic review. J Clin Virol. 2020;123:104246. https://doi.org/10.1016/j.jcv.2019.104246 .
doi: 10.1016/j.jcv.2019.104246
pubmed: 31927151
Legoff J, Péré H, Bélec L. Diagnosis of genital herpes simplex virus infection in the clinical laboratory. Virol J. 2014;11:83.
pubmed: 24885431
pmcid: 4032358
Ngo TD, Laeyendecker O, La H, Hogrefe W, Morrow RA, Quinn TC. Use of commercial enzyme immunoassays to detect antibodies to the herpes simplex virus type 2 glycoprotein g in a low-risk population in Hanoi. Vietnam Clin Vaccine Immunol. 2008;15:382–4.
pubmed: 18077617
Durdu M, Baba M, Seçkin D. The value of Tzanck smear test in diagnosis of erosive, vesicular, bullous, and pustular skin lesions. J Am Acad Dermatol. 2008;59:958–64.
pubmed: 18929431
Noyan MA, Durdu M, Eskiocak AH. TzanckNet: a convolutional neural network to identify cells in the cytology of erosive-vesiculobullous diseases. Sci Rep. 2020;10:1–7.
Burrows J, Nitsche A, Bayly B, Walker E, Higgins G, Kok T. Detection and subtyping of Herpes simplex virus in clinical samples byLightCycler PCR, enzyme immunoassay and cell culture. BMC Microbiol. 2002;2:1–7.
Fyfe JA, Keller PM, Furman PA, Miller RL, Elion GB. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem. 1978;253:8721–7.
pubmed: 214430
Tyring SK, Douglas JM, Corey L, Spruance SL, Esmann J. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol. 1998;134:185–91.
pubmed: 9487210
Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2006;42:8–13.
pubmed: 16323085
Bryson YJ, Dillon M, Lovett M, Acuna G, Taylor S, Cherry JD, et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. N Engl J Med. 1983;308:916–21.
pubmed: 6339923
Fife K, Barbarash RA, Rudolph T, Degregorio B, Roth R. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Sex Transm Dis. 1997;24:481–6.
pubmed: 9293612
Reichman RC, Badger GJ, Mertz GJ, Corey L, Richman DD, Connor JD, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. JAMA J Am Med Assoc. 1984;251:2103.
Fife KH, Almekinder J, Ofner S. A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. Sex Transm Dis. 2007;34:297–301.
pubmed: 16960547
Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran S. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. JAMA. 1996;276:44.
pubmed: 8667538
Douglas JM, Critchlow C, Benedetti J, Mertz GJ, Connor JD, Hintz MA, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med. 1984;310:1551–6.
pubmed: 6328298
Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003;16:114–28.
pubmed: 12525428
pmcid: 145299
Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HH. Herpes simplex virus resistant to acyclovir. A study in tertiary care center. Ann Intern Med. 1990;112:416–22.
pubmed: 2155570
Chen Y, Scieux C, Garrait V, Socié G, Rocha V, Molina J, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis. 2000;31:927–35.
pubmed: 11049772
Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother. 1992;36:1589–95.
pubmed: 1416838
pmcid: 191999
Safrin S, Elbeik T, Phan L, Robinson D, Rush J, Elbaggari A, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1994;38:1246–50.
pubmed: 8092821
pmcid: 188193
Lalezari J, Schacker T, Feinberg J, Gathe J, Lee S, Cheung T, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis. 1997;176:892–8.
pubmed: 9333146
Castelo-Soccio L, Bernardin R, Stern J, Goldstein S, Kovarik C. Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir. Arch Dermatol. 2010;146:124.
pubmed: 20157021
pmcid: 2874880
Wanat KA, Gormley RH, Rosenbach M, Kovarik CL. Intralesional cidofovir for treating extensive genital verrucous herpes simplex virus infection. JAMA Dermatol. 2013;149:881–3.
pubmed: 23864092
Wagstaff AJ, Bryson HM. Foscarnet—a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994;48:199–226.
pubmed: 7527325
Vandercam B, Moreau M, Goffin E, Marot JC, Cosyns JP, Jadoul M. Cidofovir-induced end-stage renal failure. Clin Infect Dis. 1999;29:948–9.
pubmed: 10589927
Kim JH, Schaenman JM, Ho DY, Brown JMY. Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients. Biol Blood Marrow Transplant. 2011;17:259–64.
pubmed: 20615475
Gilbert J, Drehs MM, Weinberg JM. Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. Arch Dermatol. 2001;137:1015–7.
pubmed: 11493093
Bernstein DI, Cardin RD, Smith GA, Pickard GE, Sollars PJ, Dixon DA, et al. The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model. npj Vaccines. 2020;5:1–8.
Magaret AS, Mujugira A, Hughes JP, Lingappa J, Bukusi EA, Debruyn G, et al. Effect of condom use on per-act HSV-2 transmission risk in HIV-1, HSV-2-discordant couples. Clin Infect Dis. 2015;62:456–61.
pubmed: 26578538
pmcid: 4725379
Wald A, Langenberg AGM, Link K, Izu AE, Ashley R, Warren T, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. J Am Med Assoc. 2001;285:3100–6.
Mujugira A, Magaret AS, Celum C, Baeten JM, Lingappa JR, Morrow RA, et al. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: A randomized controlled trial. J Infect Dis. 2013;208:1366–74.
pubmed: 23901094
pmcid: 3789565
Delaney S, Gardella C, Daruthayan C, Saracino M, Drolette L, Corey L, et al. A prospective cohort study of partner testing for herpes simplex virus and sexual behavior during pregnancy. J Infect Dis. 2012;206:486–94.
pubmed: 22693233
pmcid: 3491733
Brown ZA, Wald A, Morrow RA, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. J Am Med Assoc. 2003;289:203–9.
ACOG. Management of genital herpes in pregnancy. Obstet Gynecol. 2020;135:e193-202.
Stone KM, Reiff-Eldridge R, White AD, Cordero JF, Brown Z, Alexander ER, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984–1999. Birth Defects Res Part A Clin Mol Teratol. 2004;70:201–7.
Sheffield JS, Hill JB, Hollier LM, Laibl VR, Roberts SW, Sanchez PJ, et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery. Obstet Gynecol. 2006;108:141–7.
pubmed: 16816068
Beymer MR, Weiss RE, Bolan RK, Rudy ET, Bourque LB, Rodriguez JP, et al. Sex on demand: Geosocial networking phone apps and risk of sexually transmitted infections among a cross-sectional sample of men who have sex with men in Los Angeles county. Sex Transm Infect. 2014;90:567–72.
pubmed: 24926041
pmcid: 4198579
Ness RB, Smith KJ, Chang CCH, Schisterman EF, Bass DC. Prediction of pelvic inflammatory disease among young, single, sexually active women. Sex Transm Dis. 2006;33:137–42.
pubmed: 16505735
Lewnard JA, Berrang-Ford L. Internet-based partner selection and risk for unprotected anal intercourse in sexual encounters among men who have sex with men: a meta-analysis of observational studies. Sex Transm Infect. 2014;90:290–6.
pubmed: 24518249
Niccolai LM, Ethier KA, Kershaw TS, Lewis JB, Meade CS, Ickovics JR. New sex partner acquisition and sexually transmitted disease risk among adolescent females. J Adolesc Health. 2004;34:216–23.
pubmed: 14967345
Chan PA, Robinette A, Montgomery M, Almonte A, Cu-Uvin S, Lonks JR, et al. Extragenital infections caused by chlamydia trachomatis and neisseria gonorrhoeae: a review of the literature. Infect Dis Obstet Gynecol. 2016;2016:5758387.
pubmed: 27366021
pmcid: 4913006
USPSTF Guidelines [Internet]. [cited 2021 Jul 4]. https://www.uspreventiveservicestaskforce.org . Accessed 1 Feb 2021.